SCHEMBL1167032

SCHEMBL1167032

COC(=O)c1ncoc1-c1cccc(C(O[SiH](C)C)C(C)(C)C)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 4/20 0.39
▸ FBP1 P09467 1/20 0.37
▸ ADRB2 P07550 2/20 0.37
▸ ADRB1 P08588 2/20 0.37
▸ ADRB3 P13945 2/20 0.37
▸ KMT2A Q03164 4/20 0.37
▸ MEN1 O00255 3/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ FPR2 P25090 3/20 0.36
▸ ADORA2A P29274 1/20 0.36
▸ HCRTR2 O43614 3/20 0.34
▸ F2 P00734 1/20 0.33
▸ F10 P00742 1/20 0.33
▸ PRSS1 P07477 1/20 0.33
▸ PRSS2 P07478 1/20 0.33
▸ PRSS3 P35030 1/20 0.33
▸ LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4730224 0.78 ATR (0.46) —
SCHEMBL9125394 0.74 GSK3B (0.64) GSK3BFBP1KMT2AMEN1KDM4E
SCHEMBL1167327 0.73 GSK3B (0.43) GSK3BFBP1KMT2AMEN1ALDH1A1
SCHEMBL1969272 0.73 ADORA2A (0.64) GSK3BFBP1KMT2AMEN1KDM4E
SCHEMBL1167542 0.73 FBP1 (0.47) GSK3BFBP1KMT2AMEN1KDM4E
SCHEMBL1969052 0.72 HCRTR2 (0.50) GSK3BFBP1KMT2AMEN1KDM4E
SCHEMBL1166876 0.72 GSK3B (0.50) GSK3BFBP1KMT2AMEN1ADORA2A
SCHEMBL5470802 0.71 HCRTR2 (0.50) GSK3BFBP1KMT2AMEN1ADORA2A
SCHEMBL5474080 0.71 LOXL2 (0.51) GSK3BFBP1KMT2AMEN1ADORA2A
SCHEMBL1166776 0.71 GSK3B (0.49) GSK3BFBP1KMT2AMEN1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2242743-B1 AMINOPYRAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2013-08-21 — — EP disclosed
US-8288419-B2 Aminopyrazole derivatives ACTELION PHARMACEUTICALS, LTD (CH) 2012-10-16 — — US disclosed
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES ACTELION (CH) 2011-02-10 — — US disclosed
EP-2242743-A1 AMINOPYRAZOLE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-10-27 — — EP disclosed
WO-2009077954-A1 AMINOPYRAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-06-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES CYP3A43, CYP1A2, CYP3A5 GSK3B 2540/4885FBP1 1879/4885ADRB2 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback